The difficult management of depressive symptoms in a patient with Myasthenia Gravis: A case report

Bruno Garcia Pereira, Guilherme José Barreto Alcântara, Júlio César¿ ¿Garcia de Alencar and Rebeca Rebeca

Salud Integral y Comunitaria, 2025, vol. 3, 113-113

Abstract: Introduction: Depression in patients with Myasthenia Gravis (MG) can be multifactorial, involving biological, psychological, and social factors. Depressive manifestations may arise as a result of the emotional impact of a chronic and potentially disabling condition, as well as from neurobiological changes associated with the disease or immunosuppressive treatment. Method: In this article, we report a case of a 51-year-old man diagnosed with MG and concomitant depressive symptoms. Treatment was initiated with sertraline 150 mg/day and trazodone 50 mg/day. Results: The choice of psychotropics should be made with caution, opting for drugs with a lower likelihood of affecting neuromuscular function. SSRIs are the most effective drugs for treating depression in patients with MG, and it is advisable to avoid drugs with anticholinergic effects, such as tricyclics and haloperidol. Conclusion: Caution is important when prescribing psychotropic medications to patients with MG due to the risk of affecting neuromuscular transmission.

Date: 2025
References: Add references at CitEc
Citations:

There are no downloads for this item, see the EconPapers FAQ for hints about obtaining it.

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:dbk:sicomu:2025v3a50

DOI: 10.62486/sic2025113

Access Statistics for this article

More articles in Salud Integral y Comunitaria from AG Editor (Paraguay)
Bibliographic data for series maintained by Javier Gonzalez-Argote ().